BioSpace54m
Takeda Puts Up to $1.3B on the Line for Keros’ Blood Cancer Anemia Drug
Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...
BioSpace1h
Takeda Puts Over $1.1B on the Line for Keros’ Blood Cancer Anemia Drug
Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...
BioSpace1h
Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M
The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to ...
BioSpace2h
Gilead Plots ADC Comeback with Potential $465M License Agreement
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...
BioSpace2h
Making the Grade: Drexel’s Biomedical Sciences Programs Boost Careers at All Stages
At Drexel University’s Graduate School of Biomedical Sciences and Professional Studies, graduate students and active ...
BioSpace3h
Alligator Axes 70% of Staff Amid ‘Capital Constraints,’ Renews Pancreatic Cancer Focus
Alongside the layoffs, Alligator will also suspend work on all of its earlier-stage assets and devote its resources to lead ...